Atomoxetine in the Treatment of Binge Eating Disorder

Phase 4 Completed Lindner Center of HOPE University of Cincinnati · collab

RandomizedParallel-groupDouble-blind

Summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Timeline

Start: 2006-05
Primary completion: 2007-03
Completion: 2007-03

Outcome

Met primary endpoint

paper Compared with placebo (N = 20), atomoxetine (N = 20) was associated with a significantly greater rate of reduction in binge-eating episode frequency PMID 17388708 ↗

Publications

Results McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. doi: 10.4088/jcp.v68n0306.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atomoxetine	Other / unclassified	—	—